222 related articles for article (PubMed ID: 30776001)
1. Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease.
Wang X; Zimmermann HR; Ma T
J Alzheimers Dis; 2019; 68(1):33-38. PubMed ID: 30776001
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.
Ma T; Chen Y; Vingtdeux V; Zhao H; Viollet B; Marambaud P; Klann E
J Neurosci; 2014 Sep; 34(36):12230-8. PubMed ID: 25186765
[TBL] [Abstract][Full Text] [Related]
3. Roles of AMP-activated protein kinase in Alzheimer's disease.
Cai Z; Yan LJ; Li K; Quazi SH; Zhao B
Neuromolecular Med; 2012 Mar; 14(1):1-14. PubMed ID: 22367557
[TBL] [Abstract][Full Text] [Related]
4. Isoform-specific effects of neuronal inhibition of AMPK catalytic subunit on LTD impairments in a mouse model of Alzheimer's disease.
Yang Q; Zhou X; Ma T
Neurobiol Aging; 2024 Aug; 140():116-121. PubMed ID: 38763076
[TBL] [Abstract][Full Text] [Related]
5. AMP-activated protein kinase: a potential player in Alzheimer's disease.
Salminen A; Kaarniranta K; Haapasalo A; Soininen H; Hiltunen M
J Neurochem; 2011 Aug; 118(4):460-74. PubMed ID: 21623793
[TBL] [Abstract][Full Text] [Related]
6. Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Liu D; Tang H; Li XY; Deng MF; Wei N; Wang X; Zhou YF; Wang DQ; Fu P; Wang JZ; Hébert SS; Chen JG; Lu Y; Zhu LQ
Mol Ther; 2017 Mar; 25(3):752-764. PubMed ID: 28202389
[TBL] [Abstract][Full Text] [Related]
7. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
Munoz L; Ammit AJ
Neuropharmacology; 2010 Mar; 58(3):561-8. PubMed ID: 19951717
[TBL] [Abstract][Full Text] [Related]
8. The Bewildering Effect of AMPK Activators in Alzheimer's Disease: Review of the Current Evidence.
Assefa BT; Tafere GG; Wondafrash DZ; Gidey MT
Biomed Res Int; 2020; 2020():9895121. PubMed ID: 32149150
[TBL] [Abstract][Full Text] [Related]
9. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
O' Neill C
Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
[TBL] [Abstract][Full Text] [Related]
10. Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.
Zimmermann HR; Yang W; Kasica NP; Zhou X; Wang X; Beckelman BC; Lee J; Furdui CM; Keene CD; Ma T
J Clin Invest; 2020 Jul; 130(7):3511-3527. PubMed ID: 32213711
[TBL] [Abstract][Full Text] [Related]
11. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
[TBL] [Abstract][Full Text] [Related]
12. AMPK: A bridge between diabetes mellitus and Alzheimer's disease.
Chen M; Huang N; Liu J; Huang J; Shi J; Jin F
Behav Brain Res; 2021 Feb; 400():113043. PubMed ID: 33307136
[TBL] [Abstract][Full Text] [Related]
13. Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer's disease.
Wang X; Zhou X; Uberseder B; Lee J; Latimer CS; Furdui CM; Keene CD; Montine TJ; Register TC; Craft S; Shively CA; Ma T
Neurobiol Dis; 2021 Oct; 158():105463. PubMed ID: 34363967
[TBL] [Abstract][Full Text] [Related]
14. Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer's Disease.
Majd S; Power JHT
Curr Alzheimer Res; 2018; 15(8):764-776. PubMed ID: 29473507
[TBL] [Abstract][Full Text] [Related]
15. Activation of the 5'-AMP-Activated Protein Kinase in the Cerebral Cortex of Young Senescence-Accelerated P8 Mice and Association with GSK3β- and PP2A-Dependent Inhibition of p-tau₃₉₆ Expression.
Kim HS; Moon S; Paik JH; Shin DW; Kim LS; Park CS; Ha J; Kang JH
J Alzheimers Dis; 2015; 46(1):249-59. PubMed ID: 25737046
[TBL] [Abstract][Full Text] [Related]
16. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.
Dobarro M; Gerenu G; Ramírez MJ
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2245-57. PubMed ID: 23768694
[TBL] [Abstract][Full Text] [Related]
17. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.
Luo J; Lee SH; VandeVrede L; Qin Z; Ben Aissa M; Larson J; Teich AF; Arancio O; D'Souza Y; Elharram A; Koster K; Tai LM; LaDu MJ; Bennett BM; Thatcher GR
Mol Neurodegener; 2016 Apr; 11():35. PubMed ID: 27129593
[TBL] [Abstract][Full Text] [Related]
18. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo.
Domise M; Didier S; Marinangeli C; Zhao H; Chandakkar P; Buée L; Viollet B; Davies P; Marambaud P; Vingtdeux V
Sci Rep; 2016 May; 6():26758. PubMed ID: 27230293
[TBL] [Abstract][Full Text] [Related]
19. Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action.
Zhao Z; Yan J; Huang L; Yang X
Biomed Pharmacother; 2024 Apr; 173():116373. PubMed ID: 38442672
[TBL] [Abstract][Full Text] [Related]
20. AMPK in Neurodegenerative Diseases.
Domise M; Vingtdeux V
Exp Suppl; 2016; 107():153-177. PubMed ID: 27812980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
